Eli Lilly to Acquire Scorpion Therapeutics and Its PI3KAlpha Cancer Program in Deal Valued at Up to $2.5 Billion
January 13, 2025
January 13, 2025
BOSTON, Massachusetts, Jan. 13 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Eli Lilly in an agreement to acquire Scorpion Therapeutics and its oral therapy, STX-478, which is being tested in clinical trials for breast cancer and other advanced solid tumors. The therapy is designed to inhibit mutations in the PI3KAlpha gene that occur in a meaningful proportion of hormone-positive breast cancers, where a significant unmet need for new treatments . . .
Ropes & Gray advised Eli Lilly in an agreement to acquire Scorpion Therapeutics and its oral therapy, STX-478, which is being tested in clinical trials for breast cancer and other advanced solid tumors. The therapy is designed to inhibit mutations in the PI3KAlpha gene that occur in a meaningful proportion of hormone-positive breast cancers, where a significant unmet need for new treatments . . .